Prognostic Utility of Hyams Histological Grading and Kadish-Morita Staging Systems for Esthesioneuroblastoma Outcomes

Diana Bell, Rami Saade, Dianna Roberts, Thomas J. Ow, Michael Kupferman, Franco DeMonte, Ehab Y. Hanna

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Esthesioneuroblastoma (ENB) is derived from the specialized olfactory neuroepithelium. Hyams grading and Kadish staging have been used to prognosticate and to guide treatment decisions. In this study, we sought to validate the prognostic utility of these systems in a large ENB cohort. We retrospectively analyzed the records of patients with ENB who had been evaluated and treated at our institution. The association of grade and stage with prognostic outcome was assessed; the Kaplan–Meier estimator was used to generate 5-year OS and DFS curves. Out of 124 cases we identified, 121 were assessed for grading and 109 for staging. Review of the tissue samples revealed that 62 % of tumors were low grade (I/II) and 21 % were high grade (III/IV); 17 % of tumors were metastasis. The OS rate was 75 % at 5 years. The DFS was 60 % at 5 years. The OS was significantly worse for metastatic ENB (low-grade ENB vs metastatic ENB p = 0.01598); the DFS was significantly worse for high grade versus low grade ENB. Of the 109 cases that had been staged, 16 % were stage A, 33 % stage B, 43 % stage C, and 8 % stage D. In the A, B, and C groups, there were no significant differences between recurrence, distant metastasis, or 5-year survival rates. Statistical significance was not reached with the T, N, M and overall staging system. Age cutoff of 65 years reliably predicted OS. High grade of ENB was significantly associated with poor outcome, while advanced stage was not associated with poor outcome in this large cohort. Grading should certainly be considered in prognostication and treatment decisions for ENB.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalHead and Neck Pathology
Volume9
Issue number1
DOIs
StatePublished - Mar 1 2015

Fingerprint

Olfactory Esthesioneuroblastoma
Neoplasm Metastasis
Neoplasms
Survival Rate

Keywords

  • Esthesioneuroblastoma
  • Hyams
  • Kadish
  • Morita

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Otorhinolaryngology

Cite this

Prognostic Utility of Hyams Histological Grading and Kadish-Morita Staging Systems for Esthesioneuroblastoma Outcomes. / Bell, Diana; Saade, Rami; Roberts, Dianna; Ow, Thomas J.; Kupferman, Michael; DeMonte, Franco; Hanna, Ehab Y.

In: Head and Neck Pathology, Vol. 9, No. 1, 01.03.2015, p. 51-59.

Research output: Contribution to journalArticle

Bell, Diana ; Saade, Rami ; Roberts, Dianna ; Ow, Thomas J. ; Kupferman, Michael ; DeMonte, Franco ; Hanna, Ehab Y. / Prognostic Utility of Hyams Histological Grading and Kadish-Morita Staging Systems for Esthesioneuroblastoma Outcomes. In: Head and Neck Pathology. 2015 ; Vol. 9, No. 1. pp. 51-59.
@article{4b7ce2acacbc41caa03e37f08f9430e7,
title = "Prognostic Utility of Hyams Histological Grading and Kadish-Morita Staging Systems for Esthesioneuroblastoma Outcomes",
abstract = "Esthesioneuroblastoma (ENB) is derived from the specialized olfactory neuroepithelium. Hyams grading and Kadish staging have been used to prognosticate and to guide treatment decisions. In this study, we sought to validate the prognostic utility of these systems in a large ENB cohort. We retrospectively analyzed the records of patients with ENB who had been evaluated and treated at our institution. The association of grade and stage with prognostic outcome was assessed; the Kaplan–Meier estimator was used to generate 5-year OS and DFS curves. Out of 124 cases we identified, 121 were assessed for grading and 109 for staging. Review of the tissue samples revealed that 62 {\%} of tumors were low grade (I/II) and 21 {\%} were high grade (III/IV); 17 {\%} of tumors were metastasis. The OS rate was 75 {\%} at 5 years. The DFS was 60 {\%} at 5 years. The OS was significantly worse for metastatic ENB (low-grade ENB vs metastatic ENB p = 0.01598); the DFS was significantly worse for high grade versus low grade ENB. Of the 109 cases that had been staged, 16 {\%} were stage A, 33 {\%} stage B, 43 {\%} stage C, and 8 {\%} stage D. In the A, B, and C groups, there were no significant differences between recurrence, distant metastasis, or 5-year survival rates. Statistical significance was not reached with the T, N, M and overall staging system. Age cutoff of 65 years reliably predicted OS. High grade of ENB was significantly associated with poor outcome, while advanced stage was not associated with poor outcome in this large cohort. Grading should certainly be considered in prognostication and treatment decisions for ENB.",
keywords = "Esthesioneuroblastoma, Hyams, Kadish, Morita",
author = "Diana Bell and Rami Saade and Dianna Roberts and Ow, {Thomas J.} and Michael Kupferman and Franco DeMonte and Hanna, {Ehab Y.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1007/s12105-014-0547-3",
language = "English (US)",
volume = "9",
pages = "51--59",
journal = "Head and Neck Pathology",
issn = "1936-055X",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Prognostic Utility of Hyams Histological Grading and Kadish-Morita Staging Systems for Esthesioneuroblastoma Outcomes

AU - Bell, Diana

AU - Saade, Rami

AU - Roberts, Dianna

AU - Ow, Thomas J.

AU - Kupferman, Michael

AU - DeMonte, Franco

AU - Hanna, Ehab Y.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Esthesioneuroblastoma (ENB) is derived from the specialized olfactory neuroepithelium. Hyams grading and Kadish staging have been used to prognosticate and to guide treatment decisions. In this study, we sought to validate the prognostic utility of these systems in a large ENB cohort. We retrospectively analyzed the records of patients with ENB who had been evaluated and treated at our institution. The association of grade and stage with prognostic outcome was assessed; the Kaplan–Meier estimator was used to generate 5-year OS and DFS curves. Out of 124 cases we identified, 121 were assessed for grading and 109 for staging. Review of the tissue samples revealed that 62 % of tumors were low grade (I/II) and 21 % were high grade (III/IV); 17 % of tumors were metastasis. The OS rate was 75 % at 5 years. The DFS was 60 % at 5 years. The OS was significantly worse for metastatic ENB (low-grade ENB vs metastatic ENB p = 0.01598); the DFS was significantly worse for high grade versus low grade ENB. Of the 109 cases that had been staged, 16 % were stage A, 33 % stage B, 43 % stage C, and 8 % stage D. In the A, B, and C groups, there were no significant differences between recurrence, distant metastasis, or 5-year survival rates. Statistical significance was not reached with the T, N, M and overall staging system. Age cutoff of 65 years reliably predicted OS. High grade of ENB was significantly associated with poor outcome, while advanced stage was not associated with poor outcome in this large cohort. Grading should certainly be considered in prognostication and treatment decisions for ENB.

AB - Esthesioneuroblastoma (ENB) is derived from the specialized olfactory neuroepithelium. Hyams grading and Kadish staging have been used to prognosticate and to guide treatment decisions. In this study, we sought to validate the prognostic utility of these systems in a large ENB cohort. We retrospectively analyzed the records of patients with ENB who had been evaluated and treated at our institution. The association of grade and stage with prognostic outcome was assessed; the Kaplan–Meier estimator was used to generate 5-year OS and DFS curves. Out of 124 cases we identified, 121 were assessed for grading and 109 for staging. Review of the tissue samples revealed that 62 % of tumors were low grade (I/II) and 21 % were high grade (III/IV); 17 % of tumors were metastasis. The OS rate was 75 % at 5 years. The DFS was 60 % at 5 years. The OS was significantly worse for metastatic ENB (low-grade ENB vs metastatic ENB p = 0.01598); the DFS was significantly worse for high grade versus low grade ENB. Of the 109 cases that had been staged, 16 % were stage A, 33 % stage B, 43 % stage C, and 8 % stage D. In the A, B, and C groups, there were no significant differences between recurrence, distant metastasis, or 5-year survival rates. Statistical significance was not reached with the T, N, M and overall staging system. Age cutoff of 65 years reliably predicted OS. High grade of ENB was significantly associated with poor outcome, while advanced stage was not associated with poor outcome in this large cohort. Grading should certainly be considered in prognostication and treatment decisions for ENB.

KW - Esthesioneuroblastoma

KW - Hyams

KW - Kadish

KW - Morita

UR - http://www.scopus.com/inward/record.url?scp=84937513056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937513056&partnerID=8YFLogxK

U2 - 10.1007/s12105-014-0547-3

DO - 10.1007/s12105-014-0547-3

M3 - Article

C2 - 24806334

AN - SCOPUS:84937513056

VL - 9

SP - 51

EP - 59

JO - Head and Neck Pathology

JF - Head and Neck Pathology

SN - 1936-055X

IS - 1

ER -